[HTML][HTML] Identification of TNFRSF1A as a novel regulator of carfilzomib resistance in multiple myeloma
J Zhao, X Yang, H Zhang, X Gu - Oncology Research, 2024 - ncbi.nlm.nih.gov
Multiple myeloma (MM) is a hematological tumor with high mortality and recurrence rate.
Carfilzomib is a new-generation proteasome inhibitor that is used as the first-line therapy for …
Carfilzomib is a new-generation proteasome inhibitor that is used as the first-line therapy for …
Gene clusters based on OLIG2 and CD276 could distinguish molecular profiling in glioblastoma
Background The molecular profiling of glioblastoma (GBM) based on transcriptomic analysis
could provide precise treatment and prognosis. However, current subtyping (classic …
could provide precise treatment and prognosis. However, current subtyping (classic …